Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev












Signal Accounts for Members
All Signal Accounts
All Contests



U.K. Halifax House Price Index YoY (SA) (Nov)A:--
F: --
P: --
France Current Account (Not SA) (Oct)A:--
F: --
P: --
France Trade Balance (SA) (Oct)A:--
F: --
P: --
France Industrial Output MoM (SA) (Oct)A:--
F: --
P: --
Italy Retail Sales MoM (SA) (Oct)A:--
F: --
P: --
Euro Zone Employment YoY (SA) (Q3)A:--
F: --
P: --
Euro Zone GDP Final YoY (Q3)A:--
F: --
P: --
Euro Zone GDP Final QoQ (Q3)A:--
F: --
P: --
Euro Zone Employment Final QoQ (SA) (Q3)A:--
F: --
P: --
Euro Zone Employment Final (SA) (Q3)A:--
F: --
Brazil PPI MoM (Oct)A:--
F: --
P: --
Mexico Consumer Confidence Index (Nov)A:--
F: --
P: --
Canada Unemployment Rate (SA) (Nov)A:--
F: --
P: --
Canada Labor Force Participation Rate (SA) (Nov)A:--
F: --
P: --
Canada Employment (SA) (Nov)A:--
F: --
P: --
Canada Part-Time Employment (SA) (Nov)A:--
F: --
P: --
Canada Full-time Employment (SA) (Nov)A:--
F: --
P: --
U.S. Personal Income MoM (Sept)A:--
F: --
P: --
U.S. PCE Price Index YoY (SA) (Sept)A:--
F: --
P: --
U.S. PCE Price Index MoM (Sept)A:--
F: --
P: --
U.S. Personal Outlays MoM (SA) (Sept)A:--
F: --
P: --
U.S. Core PCE Price Index MoM (Sept)A:--
F: --
P: --
U.S. Core PCE Price Index YoY (Sept)A:--
F: --
P: --
U.S. UMich 5-Year-Ahead Inflation Expectations Prelim YoY (Dec)A:--
F: --
P: --
U.S. Real Personal Consumption Expenditures MoM (Sept)A:--
F: --
P: --
U.S. 5-10 Year-Ahead Inflation Expectations (Dec)A:--
F: --
P: --
U.S. UMich Current Economic Conditions Index Prelim (Dec)A:--
F: --
P: --
U.S. UMich Consumer Sentiment Index Prelim (Dec)A:--
F: --
P: --
U.S. UMich 1-Year-Ahead Inflation Expectations Prelim (Dec)A:--
F: --
P: --
U.S. UMich Consumer Expectations Index Prelim (Dec)A:--
F: --
P: --
U.S. Weekly Total Rig Count--
F: --
P: --
U.S. Weekly Total Oil Rig Count--
F: --
P: --
U.S. Consumer Credit (SA) (Oct)--
F: --
P: --
China, Mainland Foreign Exchange Reserves (Nov)--
F: --
P: --
China, Mainland Exports YoY (USD) (Nov)--
F: --
P: --
China, Mainland Imports YoY (CNH) (Nov)--
F: --
P: --
China, Mainland Imports YoY (USD) (Nov)--
F: --
P: --
China, Mainland Imports (CNH) (Nov)--
F: --
P: --
China, Mainland Trade Balance (CNH) (Nov)--
F: --
P: --
China, Mainland Exports (Nov)--
F: --
P: --
Japan Wages MoM (Oct)--
F: --
P: --
Japan Trade Balance (Oct)--
F: --
P: --
Japan Nominal GDP Revised QoQ (Q3)--
F: --
P: --
Japan Trade Balance (Customs Data) (SA) (Oct)--
F: --
P: --
Japan GDP Annualized QoQ Revised (Q3)--
F: --
China, Mainland Exports YoY (CNH) (Nov)--
F: --
P: --
China, Mainland Trade Balance (USD) (Nov)--
F: --
P: --
Germany Industrial Output MoM (SA) (Oct)--
F: --
P: --
Euro Zone Sentix Investor Confidence Index (Dec)--
F: --
P: --
Canada Leading Index MoM (Nov)--
F: --
P: --
Canada National Economic Confidence Index--
F: --
P: --
U.S. Dallas Fed PCE Price Index YoY (Sept)--
F: --
P: --
U.S. 3-Year Note Auction Yield--
F: --
P: --
U.K. BRC Overall Retail Sales YoY (Nov)--
F: --
P: --
U.K. BRC Like-For-Like Retail Sales YoY (Nov)--
F: --
P: --
Australia Overnight (Borrowing) Key Rate--
F: --
P: --
RBA Rate Statement
RBA Press Conference
Germany Exports MoM (SA) (Oct)--
F: --
P: --
U.S. NFIB Small Business Optimism Index (SA) (Nov)--
F: --
P: --
Mexico Core CPI YoY (Nov)--
F: --
P: --


No matching data
Latest Views
Latest Views
Trending Topics
Top Columnists
Latest Update
White Label
Data API
Web Plug-ins
Affiliate Program
View All

No data
FORM 8.3
IRISH TAKEOVER PANEL
OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
(a) Full name of discloser | BlackRock, Inc. |
(b) Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. | N/A |
(c) Name of offeror/offeree in relation to whose relevant securities this form relates Use a separate form for each offeror/offeree | Avadel Pharmaceuticals plc |
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1) | |
(e) Date position held/dealing undertaken For an opening position disclosure, state the latest practicable date prior to the disclosure | 04 December 2025 |
(f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state "N/A" | N/A |
2. INTERESTS AND SHORT POSITIONS
If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.
Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
(Note 2)
Class of relevant security (Note 3) | $0.01 ordinary shares | ||||
Interests | Short positions | ||||
Number | % | Number | % | ||
(1) Relevant securities owned and/or controlled | 6,887,394 | 7.01% | 2,934 | 0.00% | |
(2) Cash-settled derivatives | 0 | 0.00% | 4,268 | 0.00% | |
(3) Stock-settled derivatives (including options) and agreements to purchase/ sell | 0 | 0.00% | 0 | 0.00% | |
Total | 6,887,394 | 7.01% | 7,202 | 0.00% | |
All interests and all short positions should be disclosed.
Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant security | Purchase/sale | Number of securities | Price per unit (Note 5) |
$0.01 ordinary shares | Purchase | 3,200 | USD 21.3550 |
$0.01 ordinary shares | Sale | 135 | USD 21.3550 |
(b) Cash-settled derivative transactions
Class of relevant security
Product
description
e.g. CFD
Nature of dealing
e.g. opening/ closing a long/ short position, increasing/ reducing a long/ short position
Number of
reference
securities
(Note 6)
Price
per unit
(Note 5)
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of relevant security
Product
description e.g. call
option
Writing, purchasing, selling, varying
etc.
Number of
securities to which option relates (Note 6)
Exercise
price per
unit
Type
e.g. American,
European etc.
Expiry
date
Option money
paid/
received per unit
(ii) Exercise
Class of relevant security
Product description
e.g. call option
Exercising/
exercised against
Number of securities
Exercise price per unit (Note 5)
(d) Other dealings (including transactions in respect of new securities) (Note 3)
Class of relevant security | Nature of dealing e.g. subscription, conversion, exercise | Details | Price per unit (if applicable) (Note 5) |
$0.01 ordinary shares | Return of Stock on Loan | 76,800 | N/A |
$0.01 ordinary shares | Transfer out of Shares | 15,620 | N/A |
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer.
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"
(b) Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
(c) Attachments
Is a Supplemental Form 8 attached?
NO
Date of disclosure | 05 December 2025 |
Contact name | Jana Blumenstein |
Telephone number | +44 20 7743 3650 |
Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.
NOTES ON FORM 8.3
1. See the definition of "connected fund manager" in Rule 2.2 of Part A of the Rules.
2. See the definition of "interest in a relevant security" in Rule 2.5 of Part A of the Rules and see Rule 8.6(a) and (b) of Part B of the Rules.
3. See the definition of "relevant securities" in Rule 2.1 of Part A of the Rules.
4. See the definition of "dealing" in Rule 2.1 of Part A of the Rules.
5. If the economic exposure to changes in the price of securities is limited, for example, by virtue of a stop loss arrangement relating to a spread bet, full details must be given.
6. See Rule 2.5(d) of Part A of the Rules.
7. If details included in a disclosure under Rule 8 are incorrect, they should be corrected as soon as practicable in a subsequent disclosure. Such disclosure should state clearly that it corrects details disclosed previously, identify the disclosure or disclosures being corrected, and provide sufficient detail for the reader to understand the nature of the corrections. In the case of any doubt, the Panel should be consulted.
For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.
References in these notes to "the Rules" are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END ITPPKPBPKBDDFBK
FORM 8.3
IRISH TAKEOVER PANEL
OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
(a) Full name of discloser | TIG Advisors, LLC |
(b) Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. | |
(c) Name of offeror/offeree in relation to whose relevant securities this form relates Use a separate form for each offeror/offeree | Avadel Pharmaceuticals plc |
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1) | |
(e) Date position held/dealing undertaken For an opening position disclosure, state the latest practicable date prior to the disclosure | 4 December 2025 |
(f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state "N/A" | N/A |
2. INTERESTS AND SHORT POSITIONS
If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.
Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
(Note 2)
Class of relevant security (Note 3) | US$0.01 ordinary shares | |||
Interests | Short positions | |||
Number | % | Number | % | |
(1) Relevant securities owned and/or controlled | 3,865,235 | 3.94% | ||
(2) Cash-settled derivatives | ||||
(3) Stock-settled derivatives (including options) and agreements to purchase/ sell | ||||
Total | 3,865,235 | 3.94% | ||
All interests and all short positions should be disclosed.
Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant security | Purchase/sale | Number of securities | Price per unit (Note 5) |
$0.01 ordinary shares | Purchase | 72,302 | USD 21.31 |
$0.01 ordinary shares | Purchase | 64,789 | USD 21.34 |
(b) Cash-settled derivative transactions
Class of
relevant
security
Product
description
e.g. CFD
Nature of dealing
e.g. opening/ closing a long/ short position, increasing/ reducing a long/ short position
Number of
reference
securities
(Note 6)
Price
per unit
(Note 5)
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of
relevant
security
Product
description e.g. call
option
Writing, purchasing, selling, varying
etc.
Number
of
securities
to which
option
relates
(Note 6)
Exercise
price per
unit
Type
e.g.
American,
European
etc.
Expiry
date
Option
money
paid/
received per unit
(ii) Exercise
Class of
relevant
security
Product
description
e.g. call
option
Exercising/
exercised
against
Number of
securities
Exercise
price per
unit
(Note 5)
(d) Other dealings (including transactions in respect of new securities) (Note 3)
Class of
relevant
security
Nature of dealing
e.g. subscription,
conversion, exercise
Details
Price per unit (if
applicable)
(Note 5)
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer.
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"
(b) Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
(c) Attachments
Is a Supplemental Form 8 attached?
NO
Date of disclosure | 5 December 2025 |
Contact name | Cordelia Kim |
Telephone number | +1 212-396-8669 |
Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.
NOTES ON FORM 8.3
1. See the definition of "connected fund manager" in Rule 2.2 of Part A of the Rules.
2. See the definition of "interest in a relevant security" in Rule 2.5 of Part A of the Rules and see Rule 8.6(a) and (b) of Part B of the Rules.
3. See the definition of "relevant securities" in Rule 2.1 of Part A of the Rules.
4. See the definition of "dealing" in Rule 2.1 of Part A of the Rules.
5. If the economic exposure to changes in the price of securities is limited, for example, by virtue of a stop loss arrangement relating to a spread bet, full details must be given.
6. See Rule 2.5(d) of Part A of the Rules.
7. If details included in a disclosure under Rule 8 are incorrect, they should be corrected as soon as practicable in a subsequent disclosure. Such disclosure should state clearly that it corrects details disclosed previously, identify the disclosure or disclosures being corrected, and provide sufficient detail for the reader to understand the nature of the corrections. In the case of any doubt, the Panel should be consulted.
For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.
References in these notes to "the Rules" are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END ITPFLFLEFRLEIIE
FORM 8.3
IRISH TAKEOVER PANEL
OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
(a) Full name of discloser | Trium Capital LLP |
(b) Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. | |
(c) Name of offeror/offeree in relation to whose relevant securities this form relates Use a separate form for each offeror/offeree | AVADEL PHARMACEUTICALS PLC |
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1) | |
(e) Date position held/dealing undertaken For an opening position disclosure, state the latest practicable date prior to the disclosure | 04/12/2025 |
(f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state "N/A" | N/A : |
2. INTERESTS AND SHORT POSITIONS
If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.
Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
(Note 2)
Class of relevant security (Note 3) | USD 0.01 | |||
Interests | Short positions | |||
Number | % | Number | % | |
(1) Relevant securities owned and/or controlled | 1,118,314 | 1.14 | ||
(2) Cash-settled derivatives | 21,266 | 0.02 | ||
(3) Stock-settled derivatives (including options) and agreements to purchase/ sell | ||||
Total | 1,139,580 | 1.16 | ||
All interests and all short positions should be disclosed.
Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant security | Purchase/sale | Number of securities | Price per unit (Note 5) |
USD 0.01 | Purchase | 41,620 | USD 21.325 |
USD 0.01 | Purchase | 61,278 | USD 21.3446 |
USD 0.01 | Purchase | 41,621 | USD 21.3485 |
USD 0.01 | Purchase | 52,026 | USD 21.35 |
(b) Cash-settled derivative transactions
Class of relevant security | Product description e.g. CFD | Nature of dealing e.g. opening/ closing a long/ short position, increasing/ reducing a long/ short position | Number of reference securities (Note 6) | Price per unit (Note 5) |
USD 0.01 | CFD | Increasing long position | 4,634 | USD 21.325 |
USD 0.01 | CFD | Increasing long position | 5,675 | USD 21.3498 |
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of
relevant
security
Product
description e.g. call
option
Writing, purchasing, selling, varying
etc.
Number
of
securities
to which
option
relates
(Note 6)
Exercise
price per
unit
Type
e.g.
American,
European
etc.
Expiry
date
Option
money
paid/
received per unit
(ii) Exercise
Class of
relevant
security
Product
description
e.g. call
option
Exercising/
exercised
against
Number of
securities
Exercise
price per
unit
(Note 5)
(d) Other dealings (including transactions in respect of new securities) (Note 3)
Class of
relevant
security
Nature of dealing
e.g. subscription,
conversion, exercise
Details
Price per unit (if
applicable)
(Note 5)
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer.
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"
NONE
(b) Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
NONE
(c) Attachments
Is a Supplemental Form 8 attached?
NO
Date of disclosure | 05/12/2025 |
Contact name | Andrew Crick |
Telephone number | +44 (0)20 7073 9269 |
Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END ITPFLFIEFDLEIIE
Ap27
FORM 8.3
IRISH TAKEOVER PANEL
OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
(a) Full name of discloser | Citadel Group |
(b) Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. | N/A |
(c) Name of offeror/offeree in relation to whose relevant securities this form relates Use a separate form for each offeror/offeree | AVADEL PHARMACEUTICALS PLC |
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1) | N/A |
(e) Date position held/dealing undertaken For an opening position disclosure, state the latest practicable date prior to the disclosure | 4 December 2025 |
(f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state "N/A" | N/A |
2. INTERESTS AND SHORT POSITIONS
If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.
Ap28
Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
(Note 2)
Class of relevant security (Note 3) | Common Stock ISIN IE00BDGMC594 $0.01 ordinary shares | |||
Interests | Short positions | |||
Number | % | Number | % | |
(1) Relevant securities owned and/or controlled | 987,476 | 1.00 | 245,168 | 0.24 |
(2) Cash-settled derivatives | 0 | 0.00 | 0 | 0.00 |
(3) Stock-settled derivatives (including options) and agreements to purchase/ sell | 195,400 | 0.19 | 791,800 | 0.80 |
Total | 1,182,876 | 1.20 | 1,036,968 | 1.05 |
All interests and all short positions should be disclosed.
Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant security | Purchase/sale | Number of securities | Price per unit (Note 5) |
Common | Buy Transaction | 1 | 21.2200 USD |
Common | Buy Transaction | 700 | 21.3200 USD |
Common | Buy Transaction | 608 | 21.3204 USD |
Common | Buy Transaction | 103 | 21.3209 USD |
Common | Buy Transaction | 100 | 21.3225 USD |
Common | Buy Transaction | 1,467 | 21.3242 USD |
Common | Buy Transaction | 2,284 | 21.3250 USD |
Common | Buy Transaction | 1,419 | 21.3250 USD |
Common | Buy Transaction | 384 | 21.3258 USD |
Common | Buy Transaction | 5,016 | 21.3298 USD |
Common | Buy Transaction | 35,507 | 21.3300 USD |
Common | Buy Transaction | 28 | 21.3336 USD |
Common | Buy Transaction | 233 | 21.3342 USD |
Common | Buy Transaction | 120 | 21.3350 USD |
Common | Buy Transaction | 723 | 21.3400 USD |
Common | Buy Transaction | 825 | 21.3403 USD |
Common | Buy Transaction | 760 | 21.3409 USD |
Common | Buy Transaction | 1,482 | 21.3411 USD |
Common | Buy Transaction | 114 | 21.3422 USD |
Common | Buy Transaction | 15 | 21.3427 USD |
Common | Buy Transaction | 1,240 | 21.3451 USD |
Common | Buy Transaction | 1,347 | 21.3453 USD |
Common | Buy Transaction | 1,700 | 21.3453 USD |
Common | Buy Transaction | 6,779 | 21.3460 USD |
Common | Buy Transaction | 90 | 21.3484 USD |
Common | Buy Transaction | 62 | 21.3487 USD |
Common | Buy Transaction | 535 | 21.3500 USD |
Common | Buy Transaction | 2,535 | 21.3504 USD |
Common | Buy Transaction | 911 | 21.3506 USD |
Common | Buy Transaction | 70 | 21.3507 USD |
Common | Buy Transaction | 912 | 21.3517 USD |
Common | Buy Transaction | 833 | 21.3526 USD |
Common | Buy Transaction | 3,068 | 21.3529 USD |
Common | Buy Transaction | 30 | 21.3533 USD |
Common | Buy Transaction | 647 | 21.3535 USD |
Common | Buy Transaction | 81 | 21.3537 USD |
Common | Buy Transaction | 1,200 | 21.3538 USD |
Common | Buy Transaction | 412 | 21.3538 USD |
Common | Buy Transaction | 433 | 21.3539 USD |
Common | Buy Transaction | 533 | 21.3541 USD |
Common | Buy Transaction | 3,773 | 21.3550 USD |
Common | Buy Transaction | 3,065 | 21.3550 USD |
Common | Buy Transaction | 1,373 | 21.3550 USD |
Common | Buy Transaction | 297 | 21.3550 USD |
Common | Buy Transaction | 87 | 21.3551 USD |
Common | Buy Transaction | 17 | 21.3553 USD |
Common | Buy Transaction | 239 | 21.3554 USD |
Common | Buy Transaction | 1,369 | 21.3555 USD |
Common | Buy Transaction | 10 | 21.3560 USD |
Common | Buy Transaction | 1,000 | 21.3561 USD |
Common | Buy Transaction | 6,127 | 21.3561 USD |
Common | Buy Transaction | 665 | 21.3565 USD |
Common | Buy Transaction | 3 | 21.3567 USD |
Common | Buy Transaction | 2,300 | 21.3570 USD |
Common | Buy Transaction | 30 | 21.3570 USD |
Common | Buy Transaction | 27 | 21.3570 USD |
Common | Buy Transaction | 723 | 21.3571 USD |
Common | Buy Transaction | 400 | 21.3575 USD |
Common | Buy Transaction | 2,500 | 21.3576 USD |
Common | Buy Transaction | 112 | 21.3579 USD |
Common | Buy Transaction | 431 | 21.3582 USD |
Common | Buy Transaction | 200 | 21.3590 USD |
Common | Buy Transaction | 311 | 21.3593 USD |
Common | Buy Transaction | 3,012 | 21.3593 USD |
Common | Buy Transaction | 330 | 21.3597 USD |
Common | Buy Transaction | 2,788 | 21.3598 USD |
Common | Buy Transaction | 54,526 | 21.3600 USD |
Common | Buy Transaction | 1,163 | 21.3619 USD |
Common | Buy Transaction | 18 | 21.3622 USD |
Common | Buy Transaction | 9 | 21.3633 USD |
Common | Buy Transaction | 1,301 | 21.3700 USD |
Common | Buy Transaction | 371 | 21.3757 USD |
Common | Buy Transaction | 1,039 | 21.3800 USD |
Common | Sell Transaction | 200 | 21.3200 USD |
Common | Sell Transaction | 4,600 | 21.3243 USD |
Common | Sell Transaction | 1,200 | 21.3250 USD |
Common | Sell Transaction | 9,454 | 21.3293 USD |
Common | Sell Transaction | 6,500 | 21.3299 USD |
Common | Sell Transaction | 800 | 21.3300 USD |
Common | Sell Transaction | 110 | 21.3318 USD |
Common | Sell Transaction | 5,000 | 21.3350 USD |
Common | Sell Transaction | 226 | 21.3400 USD |
Common | Sell Transaction | 401 | 21.3400 USD |
Common | Sell Transaction | 855 | 21.3431 USD |
Common | Sell Transaction | 21 | 21.3433 USD |
Common | Sell Transaction | 2,508 | 21.3450 USD |
Common | Sell Transaction | 1,231 | 21.3452 USD |
Common | Sell Transaction | 1,627 | 21.3458 USD |
Common | Sell Transaction | 310 | 21.3471 USD |
Common | Sell Transaction | 800 | 21.3475 USD |
Common | Sell Transaction | 700 | 21.3479 USD |
Common | Sell Transaction | 500 | 21.3480 USD |
Common | Sell Transaction | 2,737 | 21.3487 USD |
Common | Sell Transaction | 2,548 | 21.3492 USD |
Common | Sell Transaction | 1,016 | 21.3500 USD |
Common | Sell Transaction | 120 | 21.3507 USD |
Common | Sell Transaction | 1,230 | 21.3511 USD |
Common | Sell Transaction | 644 | 21.3522 USD |
Common | Sell Transaction | 725 | 21.3525 USD |
Common | Sell Transaction | 743 | 21.3533 USD |
Common | Sell Transaction | 296 | 21.3535 USD |
Common | Sell Transaction | 22 | 21.3536 USD |
Common | Sell Transaction | 56 | 21.3545 USD |
Common | Sell Transaction | 22,387 | 21.3550 USD |
Common | Sell Transaction | 3,065 | 21.3550 USD |
Common | Sell Transaction | 1,267 | 21.3550 USD |
Common | Sell Transaction | 407 | 21.3550 USD |
Common | Sell Transaction | 125 | 21.3550 USD |
Common | Sell Transaction | 87 | 21.3551 USD |
Common | Sell Transaction | 79 | 21.3551 USD |
Common | Sell Transaction | 2,157 | 21.3554 USD |
Common | Sell Transaction | 203 | 21.3557 USD |
Common | Sell Transaction | 25,000 | 21.3574 USD |
Common | Sell Transaction | 401 | 21.3575 USD |
Common | Sell Transaction | 41 | 21.3583 USD |
Common | Sell Transaction | 104 | 21.3588 USD |
Common | Sell Transaction | 37,948 | 21.3600 USD |
Common | Sell Transaction | 530 | 21.3613 USD |
Common | Sell Transaction | 400 | 21.3650 USD |
Common | Sell Transaction | 171 | 21.3673 USD |
Common | Sell Transaction | 1,200 | 21.3700 USD |
Common | Sell Transaction | 501 | 21.3800 USD |
Common | Sell Transaction | 1 | 21.4900 USD |
Ap29
(b) Cash-settled derivative transactions
Class of
relevant
security
Product
description
e.g. CFD
Nature of dealing
e.g. opening/ closing a long/ short position, increasing/ reducing a long/ short position
Number of
reference
securities
(Note 6)
Price
per unit
(Note 5)
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of relevant security | Product description e.g. call option | Writing, purchasing, selling, varying etc. | Number of securities to which option relates (Note 6) | Exercise price per unit | Type e.g. American, European etc. | Expiry date | Option money paid/ received per unit |
Common | Put Option | Buy Transaction | 100 | 20.0000 USD | American | 2026-03-20 | 0.0700 USD |
Common | Call Option | Buy Transaction | 4,800 | 20.0000 USD | American | 2025-12-19 | 1.3500 USD |
Common | Call Option | Buy Transaction | 200 | 15.0000 USD | American | 2026-01-16 | 6.3800 USD |
(ii) Exercise
Class of
relevant
security
Product
description
e.g. call
option
Exercising/
exercised
against
Number of
securities
Exercise
price per
unit
(Note 5)
(d) Other dealings (including transactions in respect of new securities) (Note 3)
Class of
relevant
security
Nature of dealing
e.g. subscription,
conversion, exercise
Details
Price per unit (if
applicable)
(Note 5)
Ap30
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer.
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"
None
(b) Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
None
(c) Attachments
Is a Supplemental Form 8 attached?
YES
Date of disclosure | 5 December 2025 |
Contact name | Paula Santos |
Telephone number | 020 7645 9700 |
Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.
Ap32
SUPPLEMENTAL FORM 8
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1, RULE 8.3, RULE 38.5(b) AND
RULE 38.6 OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2022
DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING
OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL AND
RIGHTS TO SUBSCRIBE FOR NEW SECURITIES
1. KEY INFORMATION
Full name of person making disclosure: | Citadel Group |
Name of offeror/offeree in relation to whose relevant securities the disclosure relates: | AVADEL PHARMACEUTICALS PLC |
2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)
Class of relevant security | Product description e.g. call option | Written or purchased | Number of securities to which option or derivative relates | Exercise price per unit | Type e.g. American, European etc. | Expiry date |
Common | Call Option | Purchased | 4,200 | 17.5 USD | American | 16/01/2026 |
Common | Put Option | Purchased | -3,100 | 12.5 USD | American | 20/03/2026 |
Common | Call Option | Purchased | 0 | 5.0 USD | American | 16/01/2026 |
Common | Call Option | Purchased | 24,200 | 22.5 USD | American | 20/03/2026 |
Common | Call Option | Purchased | 5,100 | 15.0 USD | American | 15/01/2027 |
Common | Put Option | Purchased | -100 | 7.5 USD | American | 20/03/2026 |
Common | Put Option | Purchased | -1,000 | 17.5 USD | American | 18/06/2026 |
Common | Put Option | Purchased | -200 | 17.5 USD | American | 20/03/2026 |
Common | Put Option | Purchased | -60,700 | 15.0 USD | American | 16/01/2026 |
Common | Put Option | Purchased | -900 | 25.0 USD | American | 20/03/2026 |
Common | Call Option | Purchased | 900 | 7.5 USD | American | 19/12/2025 |
Common | Call Option | Purchased | 2,200 | 20.0 USD | American | 18/06/2026 |
Common | Put Option | Purchased | -2,900 | 7.5 USD | American | 19/12/2025 |
Common | Put Option | Purchased | -100 | 20.0 USD | American | 18/06/2026 |
Common | Call Option | Purchased | 5,600 | 12.5 USD | American | 15/01/2027 |
Common | Put Option | Purchased | -4,700 | 15.0 USD | American | 19/12/2025 |
Common | Put Option | Purchased | -3,800 | 15.0 USD | American | 20/03/2026 |
Common | Put Option | Purchased | 0 | 12.5 USD | American | 15/01/2027 |
Common | Call Option | Purchased | 33,900 | 20.0 USD | American | 19/12/2025 |
Common | Call Option | Purchased | 3,000 | 25.0 USD | American | 15/01/2027 |
Common | Put Option | Purchased | -100 | 15.0 USD | American | 15/01/2027 |
Common | Call Option | Purchased | 0 | 25.0 USD | American | 20/03/2026 |
Common | Call Option | Purchased | 5,100 | 22.5 USD | American | 15/01/2027 |
Common | Put Option | Purchased | 0 | 10.0 USD | American | 20/03/2026 |
Common | Put Option | Purchased | -44,400 | 10.0 USD | American | 16/01/2026 |
Common | Put Option | Sold | 2,000 | 17.5 USD | American | 19/12/2025 |
Common | Call Option | Sold | -1,700 | 25.0 USD | American | 16/01/2026 |
Common | Call Option | Sold | -6,800 | 25.0 USD | American | 19/12/2025 |
Common | Call Option | Sold | -100 | 20.0 USD | American | 15/01/2027 |
Common | Put Option | Sold | 8,200 | 10.0 USD | American | 19/12/2025 |
Common | Put Option | Sold | 59,000 | 5.0 USD | American | 16/01/2026 |
Common | Call Option | Sold | -2,100 | 12.5 USD | American | 20/03/2026 |
Common | Call Option | Sold | -13,400 | 10.0 USD | American | 15/01/2027 |
Common | Call Option | Sold | -5,100 | 10.0 USD | American | 19/12/2025 |
Common | Call Option | Sold | -2,600 | 30.0 USD | American | 16/01/2026 |
Common | Call Option | Sold | -6,200 | 12.5 USD | American | 19/12/2025 |
Common | Call Option | Sold | -100 | 35.0 USD | American | 16/01/2026 |
Common | Call Option | Sold | -34,200 | 5.0 USD | American | 15/01/2027 |
Common | Call Option | Sold | -9,900 | 22.5 USD | American | 16/01/2026 |
Common | Put Option | Sold | 4,400 | 17.5 USD | American | 16/01/2026 |
Common | Put Option | Sold | 24,900 | 7.5 USD | American | 16/01/2026 |
Common | Call Option | Sold | -30,000 | 15.0 USD | American | 20/03/2026 |
Common | Put Option | Sold | 5,500 | 12.5 USD | American | 16/01/2026 |
Common | Call Option | Sold | -31,800 | 17.5 USD | American | 19/12/2025 |
Common | Put Option | Sold | 5,300 | 20.0 USD | American | 19/12/2025 |
Common | Put Option | Sold | 300 | 20.0 USD | American | 20/03/2026 |
Common | Call Option | Sold | -4,800 | 17.5 USD | American | 15/01/2027 |
Common | Put Option | Sold | 1,600 | 12.5 USD | American | 19/12/2025 |
Common | Call Option | Sold | -38,000 | 15.0 USD | American | 19/12/2025 |
Common | Call Option | Sold | -10,200 | 7.5 USD | American | 15/01/2027 |
Common | Call Option | Sold | -147,800 | 15.0 USD | American | 16/01/2026 |
Common | Call Option | Sold | -10,000 | 17.5 USD | American | 20/03/2026 |
Common | Call Option | Sold | -46,200 | 20.0 USD | American | 16/01/2026 |
Common | Call Option | Sold | -100 | 30.0 USD | American | 19/12/2025 |
Common | Call Option | Sold | -182,900 | 10.0 USD | American | 16/01/2026 |
Common | Call Option | Sold | -4,900 | 22.5 USD | American | 19/12/2025 |
Common | Call Option | Sold | -5,400 | 20.0 USD | American | 20/03/2026 |
Common | Call Option | Sold | -65,900 | 12.5 USD | American | 16/01/2026 |
Common | Call Option | Sold | -9,600 | 7.5 USD | American | 16/01/2026 |
3. AGREEMENTS TO PURCHASE OR SELL
Full details should be given so that the nature of the interest or position can be fully understood:
Ap33
4. RIGHTS TO SUBSCRIBE FOR NEW SECURITIES (INCLUDING DIRECTORS' AND OTHER EMPLOYEE OPTIONS)
Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:
It is not necessary to provide details on a Supplemental Form with regard to cash-settled derivatives.
The currency of all prices and other monetary amounts should be stated.
For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.
References in these notes to "the Rules" are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END ITPTABBTMTAMBMA
FORM 38.5(b)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNISED INTERMEDIARY STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY
1. KEY INFORMATION
Name of exempt principal trader | (GS) GOLDMAN SACHS INTERNATIONAL |
Company dealt in | AVADEL PHARMACEUTICALS PLC |
Class of relevant security to which the dealings being disclosed relate (Note1) | USD 0.01 ordinary shares |
Date of dealing | 04 December 2025 |
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 2)
Long | Short | |||
Number | (%) | Number | (%) | |
(1) Relevant securities | 53 | (0.00) | 1,151 | (0.00) |
(2) Derivatives (other than options) | 0 | (0.00) | 0 | (0.00) |
(3) Options and agreements to purchase/sell | 0 | (0.00) | 0 | (0.00) |
Total | 53 | (0.00) | 1,151 | (0.00) |
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 2)
Class of relevant security: | Long | Short | ||
Number | (%) | Number | (%) | |
(1) Relevant securities | ||||
(2) Derivatives (other than options) | ||||
(3) Options and agreements to purchase/sell | ||||
Total | ||||
3. DEALINGS (Note 3)
(a) Purchases and sales
Purchase/sale | Number of relevant securities | Price per unit (Note 4) |
Purchase (Loan Full Return) | 27 | N/A |
Sale (Loan New) | 27 | N/A |
Purchase (Loan Full Return) | 3 | N/A |
Sale (Loan New) | 3 | N/A |
Purchase (Borrow New) | 53 | N/A |
Sale (Borrow Partial Return) | 27 | N/A |
Purchase (Borrow New) | 30 | N/A |
Sale (Borrow Full Return) | 3 | N/A |
Sale (Borrow Full Return) | 53 | N/A |
Sale (Loan New) | 53 | N/A |
Purchase (Loan Partial Return) | 3 | N/A |
Purchase (Loan Partial Return) | 27 | N/A |
(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD
Nature of transaction (Note 5)
Number of relevant securities (Note 6)
Price per unit (Note 4)
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name,e.g. call option
Writing, selling, purchasing, varying etc.
Number of securities to which the option relates (Note 7)
Exercise price
Type, e.g. American, European etc.
Expiry date
Option money paid/received per unit (Note 4)
(ii) Exercising
Product name,e.g. call option
Number of securities
Exercise price per unit (Note 4)
(d) Other dealings (including transactions in respect of new securities) (Note 3)
Nature of transaction (Note 7)
Details
Price per unit (if applicable) (Note 4)
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
NONE
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure | 05 December 2025 |
Contact name | Papa Lette and Andrzej Szyszka |
Telephone number | +33(1) 4212 1459 / +48(22) 317 4817 |
Name of offeree/offeror with which connected | AVADEL PHARMACEUTICALS PLC |
Nature of connection (Note 9) | Advisor to Offeree |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END ITPUPGCGPUPAGCA
White Label
Data API
Web Plug-ins
Poster Maker
Affiliate Program
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.
Not Logged In
Log in to access more features

FastBull Membership
Not yet
Purchase
Log In
Sign Up